Altis Labs Raises $25M Series A Led by OrbiMed to Scale AI Endpoints for Oncology Trials

Altis Labs Closes $25M Series A

Altis Labs, a Toronto-based company building AI endpoints for oncology clinical trials, has raised $25 million in Series A funding. The round was led by OrbiMed, with participation from Lumira, Fusion Fund, Qiming Venture Partners USA, Benchstrength, and Innovation Endeavors.

The raise positions Altis Labs to expand the reach of its prognostic AI platform at a moment when biopharma sponsors are actively searching for objective, scalable measures of treatment effect in oncology studies.

What Altis Labs Does

Altis Labs develops AI endpoints designed for use in oncology clinical trials. Its core asset is IPRO, a prognostic AI model that generates survival predictions from routinely acquired radiology scans.

The model was trained with leading cancer centers on a large multimodal oncology database that links imaging, molecular, clinical, and outcomes data. That multimodal foundation is central to the company's approach: rather than relying on a single data type, IPRO draws on linked patient records to produce survival predictions intended to support trial analysis.

Traction With Top-20 Biopharma

According to the company, top-20 biopharma companies use the Altis platform to analyze Phase 1 through Phase 4 trial data. The most notable validation point cited is a Phase 3 result: the company's AI endpoint delivered Phase 3 validation in Johnson & Johnson's post-hoc analysis of the MARIPOSA lung cancer trial.

That kind of Phase 3 exposure matters for a company selling into clinical development organizations. AI-derived endpoints face a high evidentiary bar before sponsors will incorporate them into registrational or supporting analyses, and a post-hoc analysis within a late-stage lung cancer trial represents a meaningful proof point for the technology.

Why the Round Matters

The Series A brings Altis Labs $25 million in new capital and a lead investor in OrbiMed, a firm with deep healthcare and life sciences specialization. The syndicate also includes Lumira, Fusion Fund, Qiming Venture Partners USA, Benchstrength, and Innovation Endeavors, giving the company a mix of healthcare-focused and technology-oriented backers.

For a company operating at the intersection of AI and oncology drug development, the funding supports the core commercial motion: working with biopharma sponsors to embed AI-derived endpoints into trial workflows, from early-phase signal detection through late-stage validation.

The Strategic Context

Oncology remains one of the most data-rich and measurement-intensive areas of drug development. Imaging is routinely collected across trials, but extracting quantitative, prognostic signal from those scans at scale has historically been difficult. Altis Labs' proposition is that IPRO can turn existing radiology data into survival predictions that sponsors can use to analyze trial data more effectively.

The company's multimodal database — linking imaging, molecular, clinical, and outcomes data — is a differentiating asset. Models trained on linked datasets of this kind are difficult to replicate without comparable data partnerships, which the company has established with leading cancer centers.

What to Watch

With $25 million in Series A funding led by OrbiMed, Altis Labs has the capital to deepen its biopharma relationships and continue validating its AI endpoints across trial phases. The key questions for the company going forward will be the breadth of regulatory and sponsor acceptance for AI-derived endpoints, and how quickly it can convert its Phase 3 validation experience into broader adoption across oncology programs.

For acquirers and strategic partners in the clinical trial technology and AI drug development space, Altis Labs now sits in a well-capitalized position with a late-stage validation reference point and an established base of top-20 biopharma users.